EA202191706A1 - ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND THEIR APPLICATION - Google Patents

ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND THEIR APPLICATION

Info

Publication number
EA202191706A1
EA202191706A1 EA202191706A EA202191706A EA202191706A1 EA 202191706 A1 EA202191706 A1 EA 202191706A1 EA 202191706 A EA202191706 A EA 202191706A EA 202191706 A EA202191706 A EA 202191706A EA 202191706 A1 EA202191706 A1 EA 202191706A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
hepatitis
antigen
virus
relates
Prior art date
Application number
EA202191706A
Other languages
Russian (ru)
Inventor
Давиде Корти
Original Assignee
Хумабс Биомед Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хумабс Биомед Са filed Critical Хумабс Биомед Са
Priority claimed from PCT/US2019/067216 external-priority patent/WO2020132091A2/en
Publication of EA202191706A1 publication Critical patent/EA202191706A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к антителам и к их антигенсвязывающим фрагментам, которые могут связываться с областью антигенной петли поверхностного антигена гепатита B (HBsAg) и могут нейтрализовать инфекцию, вызываемую вирусом гепатита B (HBV) и вирусом гепатита дельта (HDV). Настоящее изобретение также относится к эпитопам, с которыми связываются антитела и антигенсвязывающие фрагменты, а также к гибридным белкам, которые содержат антигенсвязывающие фрагменты, и к нуклеиновым кислотам, которые кодируют их, а также к клеткам, которые продуцируют такие антитела и фрагменты антител. Кроме того, настоящее изобретение относится к применению антител и фрагментов антител согласно изобретению для диагностики, профилактики и лечения гепатита B и гепатита D.The present invention relates to antibodies and antigen-binding fragments thereof that can bind to the antigen loop region of hepatitis B surface antigen (HBsAg) and can neutralize hepatitis B virus (HBV) and hepatitis delta virus (HDV) infection. The present invention also relates to epitopes to which antibodies and antigen-binding fragments bind, as well as fusion proteins that contain antigen-binding fragments and nucleic acids that encode them, as well as cells that produce such antibodies and antibody fragments. In addition, the present invention relates to the use of antibodies and antibody fragments according to the invention for the diagnosis, prevention and treatment of hepatitis B and hepatitis D.

EA202191706A 2019-06-11 2019-12-18 ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND THEIR APPLICATION EA202191706A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860085P 2019-06-11 2019-06-11
PCT/US2019/067216 WO2020132091A2 (en) 2018-12-19 2019-12-18 Antibodies that neutralize hepatitis b virus and uses thereof

Publications (1)

Publication Number Publication Date
EA202191706A1 true EA202191706A1 (en) 2021-10-28

Family

ID=78572618

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191706A EA202191706A1 (en) 2019-06-11 2019-12-18 ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202191706A1 (en)

Similar Documents

Publication Publication Date Title
EA201890874A1 (en) ANTIBODIES THAT EFFECTIVELY NEUTRALIZE THE HEPATITIS B VIRUS AND THEIR USE
ZA202104213B (en) Antibodies that neutralize hepatitis b virus and uses thereof
EA201990243A1 (en) NEW ANTIBODIES THAT ARE SPECIFICALLY CONNECTED WITH EPIC EPITHOS OF THE ZIKA VIRUS, AND THEIR APPLICATION
EA200900033A1 (en) VACCINES AGAINST MALARIA
EA201892793A1 (en) ANTI-HLA-G SPECIFIC ANTIBODIES
EA202092933A1 (en) ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS OF APPLICATION OF ANTIBODIES AND TYPES OF COMBINATION THERAPY
JP2015146822A5 (en)
FI3459597T3 (en) Single domain antibody for ctla4 and derived protein thereof
JP2017524339A5 (en)
EA201892522A1 (en) DNA MONOCLONAL ANTIBODIES TARGED TO MOLECULES OF CONTROL POINTS
EA201391170A1 (en) THERAPEUTIC MEANS BASED ON YEAST FOR THE TREATMENT OF CHRONIC HEPATITIS B
RU2018133708A (en) BTLA SPECIFIC ANTIBODIES AND THEIR USE
CA2963470A1 (en) Antibodies that bind ebola glycoprotein and uses thereof
EA202090559A1 (en) MULTI-SPECIFIC ANTIBODIES SPECIFIC REGARDING ZIKA VIRUS EPITOPES AND THEIR APPLICATION
SG10201806025TA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
RU2014127287A (en) ANTIBODIES USED FOR PASSIVE VACCINATION AGAINST INFLUENZA
RU2017113732A (en) AN ANTIBODY THAT HAS THE ABILITY TO NEUTRALIZE AN ACTIVITY SUBSTANCE, AN ALTERNATIVE FUNCTION OF COLLECTION FACTOR VIII (FVIII)
EA202192907A1 (en) MONOCLONAL ANTIBODY THAT SPECIFICLY BINDS TO GITR
EA201992206A1 (en) MONOCLONAL ANTIBODY TO PD-L1
MX2022015765A (en) Engineered hepatitis b virus neutralizing antibodies and uses thereof.
MX2021010281A (en) Antigen binding proteins that bind bcma.
EA201500114A1 (en) ANTIBODY COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFECTION BY THE MUTANT VIRUS HEPATITIS B
EA202191706A1 (en) ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND THEIR APPLICATION
EA201892524A1 (en) DNA monoclonal antibodies targeted at IL-6 and CD126
EA201900360A1 (en) WATER PHARMACEUTICAL COMPOSITION OF RECOMBINANT MONOCLONAL ANTIBODY TO TNF